不同剂量的紫杉醇联合顺铂治疗晚期非小细胞肺癌  

PACLITAXOL OF DIFFERENT DOSES PLUS CISPLATIN IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER

作　　者：陈嘉[1] 陆禹溶[1] 黄富麟[1] 祝浩强[1] 蔡炜宇[1] 

机构地区：[1]江苏省肿瘤医院肿瘤内科

出　　处：《中国癌症杂志》1999年第2期107-108,共2页China Oncology

摘　　要：目的研究不同剂量的紫杉醇联合固定剂量的顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法第１天甲组用紫杉醇１０５ｍｇ／ｍ２，乙组用紫杉醇１８０ｍｇ／ｍ２，两组第２～５天均用顺铂４０ｍｇ／ｍ２。应用紫杉醇前予抗过敏治疗，紫杉醇均用３ｈ的静脉滴注。结果两组均无完全缓解（ＣＲ）。甲组部分缓解（ＰＲ）３６４％（４／１１），初治病人为６０％（３／５），复治为１７％（１／６）。乙组ＰＲ２８６％（４／１４），初治为４０％（２／５），复治２２％（２／９）。中性粒细胞的抑制作用甲组轻于乙组，周围神经毒性亦低于乙组。其余不良反应两组相似。结论两种剂量的紫杉醇联合固定剂量的顺铂对初治晚期非小细胞肺癌均有效，但对复治病例疗效差，特别是１０５ｍｇ／ｍ２组。PURPOSE To study the effect and toxicity of different doses of paclitaxol in the treatment of advanced non small cell lung cancer (NSCLC). METHODS Patients of a group were given paclitaxel 105 mg/m 2(3 h) d 1,cisplatin 40 mg/m 2 (d 2～4) RESULTS There were no complete relief (CR) in the A and B group. 4 of 11 cases of A group reached partial relief (PR) (36.4%),3 of which were previously untreated cases (3/5,60%).1 of 6 was a previously treated case (17%).4 of 14 case of B group reached PR(28.6%),2 of 5 of which were previously untreated cases (40%),2 of 9 of were previously treated cases (22%).Leukopenia and peripheral neuropathy of A group were less than B group,other toxicities were similar. CONCLUSIONS Two doses of paclitaxol plus cisplatinare are effective for previously untreated advanced NSCLC,but less effective for previously treated cases especially with a dose of 105 mg/m 2.

关 键 词：紫杉醇 剂量 疗效 化疗 顺铂 肺肿瘤 

分 类 号：R734.205[医药卫生—肿瘤] R730.53[医药卫生—临床医学]